Patents by Inventor Toshihiko Kaneko
Toshihiko Kaneko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120026642Abstract: Disclosed is a multilayer ceramic electronic component, comprising an element body obtained by stacking dielectric layers (thickness t1) and electrode layers (thickness t2). The dielectric layer (2) includes a compound expressed by ABO3 (A includes Ba, and may include Ca or Sr; and B includes Ti, and may include Zr or Hf), and includes 0.75 to 2.0 moles of MgO, 0.4 to 1.0 mole of an oxide of Y, Dy, Ho and the like in terms of the oxide, and 0.4 to 0.8 mole of SiO2 per 100 moles of the compound. A segregation phase (20) containing Mg is formed in at least a part of an electrode missing portion (30), where the electrode layer is supposed to be formed but no electrode layer is formed. Line coverage of the electrode layer (3) is 60 to 90% and relations of 0.3?t1?2.0 and 0.3?t2<1.0 are fulfilled.Type: ApplicationFiled: July 25, 2011Publication date: February 2, 2012Applicant: TDK CORPORATIONInventors: Toshihiko KANEKO, Ryutaro YAMAZAKI, Taisuke MASUKO, Yusuke SATO, Yasushi MATSUYAMA, Yasuo WATANABE, Masakazu HOSONO, Saori TAKEDA, Hirobumi TANAKA, Makoto ENDO
-
Publication number: 20120012002Abstract: To develop a means for effectively utilize terpene compounds contained in tree leaves, whereby branches and leaves cut in tree thinning and pruning can be effectively utilized as a resource. For this purpose, provided are a monoterpene component-rich essential oil containing 90% or more of monoterpene components; a method for producing the monoterpene component-rich essential oil which includes subjecting coniferous leaves to microwave steam distillation and collecting a distillate thus obtained; and a method for removing environmental pollutants which includes bringing the monoterpene component-rich essential oil into contact with atmosphere containing the environmental pollutants.Type: ApplicationFiled: February 26, 2010Publication date: January 19, 2012Applicant: Japan Aroma Laboratory Co., Ltd.Inventors: Toshihiko Kaneko, Yuichi Tanaka, Tatsuro Ohira, Naoyuki Matsui
-
Patent number: 8048878Abstract: The present invention relates to a novel two cyclic cinnamide compound and a pharmaceutical agent comprising the compound as an active ingredient. The two cyclic cinnamide compound represented by the general formula (I): wherein represents a single bond or a double bond; Ar1 represents a phenyl group or pyridinyl group that may be substituted with 1 to 3 substituents; R1 and R2 each represent a C1-6 alkyl group, a hydroxyl group, or the like; Z1 represents a methylene group or vinylene group, which may be substituted with 1 or 2 substituents selected from Substituent Group A1, an oxygen atom, or an imino group that may be substituted with a substituent selected from Substituent Group A1; and p, q, and r each represent an integer of 0 to 2, which has an effect of reducing A?40 and A?42 production, and thus is particularly useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? such as Alzheimer's disease or Down's syndrome.Type: GrantFiled: March 13, 2009Date of Patent: November 1, 2011Assignee: Eisai R&D Management Co., Ltd.Inventors: Teiji Kimura, Koki Kawano, Eriko Doi, Noritaka Kitazawa, Mamoru Takaishi, Koichi Ito, Toshihiko Kaneko, Takeo Sasaki, Takehiko Miyagawa, Hiroaki Hagiwara, Yu Yoshida
-
Patent number: 8008293Abstract: The present invention relates to a compound represented by formula (I): wherein R1 represents a C1-3 alkyl group, R2 represents a hydrogen atom or a C1-3 alkyl group, Ar represents a phenyl group or the like which may be substituted with 1 to 3 substituents, X represents an oxygen atom or the like, n and m are the same or different and integers of 0 to 2, or a pharmacologically acceptable salt, and use thereof as a medicament.Type: GrantFiled: February 27, 2008Date of Patent: August 30, 2011Assignee: Eisai R&D Management Co., Ltd.Inventors: Teiji Kimura, Koki Kawano, Eriko Doi, Noritaka Kitazawa, Mamoru Takaishi, Koichi Ito, Toshihiko Kaneko, Takeo Sasaki, Nobuaki Sato, Takehiko Miyagawa, Hiroaki Hagiwara
-
Patent number: 7973033Abstract: The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by A?.Type: GrantFiled: January 12, 2011Date of Patent: July 5, 2011Assignee: Eisai R&D Management Co., Ltd.Inventors: Teiji Kimura, Noritaka Kitazawa, Toshihiko Kaneko, Nobuaki Sato, Koki Kawano, Koichi Ito, Eriko Doi, Mamoru Takaishi, Takeo Sasaki, Takehiko Miyagawa, Hiroaki Hagiwara, Takashi Doko
-
Publication number: 20110152253Abstract: A compound represented by the general formula (I): or a pharmaceutically acceptable salt thereof, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.Type: ApplicationFiled: July 24, 2009Publication date: June 23, 2011Applicant: Eisai R&D Management Co., LtdInventors: Takafumi Motoki, Toshihiko Kaneko, Noboru Yamamoto, Afzal Khan
-
Publication number: 20110112138Abstract: The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by A?.Type: ApplicationFiled: January 12, 2011Publication date: May 12, 2011Inventors: Teiji KIMURA, Noritaka KITAZAWA, Toshihiko KANEKO, Nobuaki SATO, Koki KAWANO, Koichi ITO, Eriko DOI, Mamoru TAKAISHI, Takeo SASAKI, Takehiko MIYAGAWA, Hiroaki HAGIWARA, Takashi DOKO
-
Publication number: 20110105427Abstract: The present invention provides compounds having formula (I): wherein R1, R2, R3 and n are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of inflammatory or autoimmune and proliferative disorders and as inhibitors of cell adhesion molecule expression and inflammatory cytokine signal transduction generally.Type: ApplicationFiled: November 2, 2010Publication date: May 5, 2011Inventors: Jane Daun, Heather A. Davis, Bruce DeCosta, Fabian Gusovsky, Ieharu Hishinuma, Yimin Jiang, Toshihiko Kaneko, Kouichi Kikuchi, Seiichi Kobayashi, André Lescarbeau, Xiang-Yi Li, Kenzo Muramoto, Norihito Ohi, Marc Pesant, Boris M. Seletsky, Motohiro Soejima, Mark Spyvee, Lynda Tremblay, Ye Yao, Hiromitsu Yokohama, Yan (Janet) Zhao, Wanjun Zheng
-
Patent number: 7935815Abstract: A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X1 represents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by A?.Type: GrantFiled: August 28, 2008Date of Patent: May 3, 2011Assignee: Eisai R&D Management Co., Ltd.Inventors: Teiji Kimura, Noritaka Kitazawa, Toshihiko Kaneko, Nobuaki Sato, Koki Kawano, Koichi Ito, Mamoru Takaishi, Takeo Sasaki, Yu Yoshida, Toshiyuki Uemura, Takashi Doko, Daisuke Shinmyo, Daiju Hasegawa, Takehiko Miyagawa, Hiroaki Hagiwara
-
Publication number: 20110086860Abstract: A compound represented by Formula (I) is provided: wherein Ar1 represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar2 represents a phenyl group which may be substituted with 1 to 3 substituents; X1 represents (1) —C?C— or (2) a double bond etc., which may be substituted; R1 and R2 represent, for example, a C1-6 alkyl group which may be substituted, or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents.Type: ApplicationFiled: December 21, 2010Publication date: April 14, 2011Inventors: Teiji KIMURA, Koki Kawano, Eriko Doi, Noritaka Kitazawa, Kogyoku Shin, Takehiko Miyagawa, Toshihiko Kaneko, Koichi Ito, Mamoru Takaishi, Takeo Sasaki, Hiroaki Hagiwara
-
Publication number: 20110065696Abstract: A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X1 represents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by A?.Type: ApplicationFiled: November 19, 2010Publication date: March 17, 2011Inventors: Teiji KIMURA, Noritaka Kitazawa, Toshihiko Kaneko, Nobuaki Sato, Koki Kawano, Koichi Ito, Mamoru Takaishi, Takeo Sasaki, Yu Yoshida, Toshiyuki Uemura, Takashi Doko, Daisuke Shinmyo, Daiju Hasegawa, Takehiko Miyagawa, Hiroaki Hagiwara
-
Patent number: 7897632Abstract: The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by A?.Type: GrantFiled: March 11, 2010Date of Patent: March 1, 2011Assignee: Eisai R&D Management Co., Ltd.Inventors: Teiji Kimura, Noritaka Kitazawa, Toshihiko Kaneko, Nobuaki Sato, Koki Kawano, Koichi Ito, Eriko Doi, Mamoru Takaishi, Takeo Sasaki, Takehiko Miyagawa, Hiroaki Hagiwara, Takashi Doko
-
Patent number: 7880009Abstract: The present invention relates to a compound represented by Formula (I): (wherein Ar1 represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar2 represents a pyridinyl group, a pyrimidinyl group, or a phenyl group which may be substituted with 1 to 3 substituents; X1 represents (1) —C?C— or (2) a double bond etc. which may be substituted; R1 and R2 represent, for example, a C1-6 alkyl group or C3-8 cycloalkyl group which may be substituted) or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents.Type: GrantFiled: May 25, 2005Date of Patent: February 1, 2011Assignee: Eisai R&D Management Co., Ltd.Inventors: Teiji Kimura, Koki Kawano, Eriko Doi, Noritaka Kitazawa, Kogyoku Shin, Takehiko Miyagawa, Toshihiko Kaneko, Koichi Ito, Mamoru Takaishi, Takeo Sasaki, Hiroaki Hagiwara
-
Publication number: 20110009619Abstract: Disclosed is a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, which is effective as a therapeutic or prophylactic agent for a disease induced by A?, wherein Ar1 represents an imidazolyl group which may be substituted with a C1-6 alkyl group, or the like; Ar2 represents a phenyl group which may be substituted with a C1-6 alkoxy group, or the like; X1 represents a double bond, or the like; and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, or the like.Type: ApplicationFiled: August 28, 2008Publication date: January 13, 2011Applicant: Eisai R&D Management Co., Ltd.Inventors: Teiji Kimura, Noritaka Kitazawa, Toshihiko Kaneko, Nobuaki Sato, Koki Kawano, Koichi Ito, Mamoru Takaishi, Takeo Sasaki, Yu Yoshida, Toshiyuki Uemura, Takashi Doko, Daisuke Shinmyo, Daiju Hasegawa, Takehiko Miyagawa, Hiroaki Hagiwara
-
Patent number: 7868002Abstract: As discussed above, there remains a need for the development of novel therapeutic agents useful for treating inflammatory or autoimmune and proliferative diseases. The present invention provides novel compounds of general formula (I), and pharmaceutical compositions thereof, as described generally and in classes and subclasses herein, as well as methods of making and using such compounds.Type: GrantFiled: September 28, 2007Date of Patent: January 11, 2011Assignee: Eisai R&D Management Co., Ltd.Inventors: Jane Daun, Heather A. Davis, Bruce DeCosta, Fabian Gusovsky, Ieharu Hishinuma, Yimin Jiang, Toshihiko Kaneko, Kouichi Kikuchi, Seiichi Kobayashi, André Lescarbeau, Xiang-Yi Li, Kenzo Muramoto, Norihito Ohi, Marc Pesant, Boris M. Seletsky, Motohiro Soejima, Mark Spyvee, Lynda Tremblay, Ye Yao, Hiromitsu Yokohama, Yan (Janet) Zhao, Wanjun Zheng
-
Publication number: 20100331310Abstract: Compounds represented by formula (I) and pharmaceutically acceptable salts thereof have excellent sodium channel inhibitory action and are useful as therapeutic agents and analgesics for various kinds of neuralgia, neuropathy, epilepsy, insomnia, premature ejaculation and the like. wherein Q represents ethylene, etc., R1, R2 and R3 represent hydrogen, etc., X1 represents C1-6 alkylene, etc., X2 represents C1-6 alkylene, etc., A1 represents a 5- to 6-membered heterocyclic group, etc., and A2 represents C6-14 aryl, etc.Type: ApplicationFiled: February 9, 2009Publication date: December 30, 2010Inventors: Fumihiro Ozaki, Motohiro Soejima, Tasuku Ishida, Yoshihiko Norimine, Nobuyuki Kurusu, Eriko Doi, Toshihiko Kaneko, Daiju Hasegawa, Kiyoaki Kobayashi, Noboru Yamamoto
-
Publication number: 20100317850Abstract: Disclosed is a compound represented by General formula (I), a pharmaceutically acceptable salt thereof, or a solvate of the compound or the pharmaceutically acceptable salt, which has an inhibitory activity of the production of A? or a BACE1-inhibiting activity, and is therefore useful as a prophylactic or therapeutic agent for A?-induced neurodegenerative diseases typified by Alzheimer-type dementia. Wherein the ring A represents a C6-14 aryl group or the like; L represents —NReCO— [wherein Re represents a hydrogen atom or the like] or the like; the ring B represents a C6-14 aryl group or the like; X represents a C1-3 alkylene group or the like; Y represents a single bond or the like; Z represents a C1-3 alkylene group or the like; R1 and R2 independently represent a hydrogen atom or the like; and R3, R4, R5 and R6 independently represent a hydrogen atom, a halogen atom or the like.Type: ApplicationFiled: January 16, 2009Publication date: December 16, 2010Inventors: Yuichi Suzuki, Takafumi Motoki, Toshihiko Kaneko, Mamoru Takaishi, Tasuku Ishida, Kunitoshi Takeda, Yoichi Kita, Noboru Yamamoto, Afzal Khan, Paschalis Dimopoulos
-
Patent number: 7759269Abstract: A dielectric ceramic composition of the invention comprises: BaTiO3 as a main component, MgO: 0.50 to 3.0 moles, MnO: 0.05 to 0.5 moles, oxide (RE12O3) of element selected from Sm, Eu, and Gd, oxide (RE22O3) of element selected from Tb and Dy, oxide (RE32O3) of element selected from Y, Ho, Er, Yb, Tm and Lu, BaZrO3: 0.20 to 1.0 moles, and oxide of element selected from V, Ta, Mo, Nb, and W: 0.05 to 0.25 moles as subcomponents wherein each subcomponent is calculated as a conversion of an oxide or composite oxide, with respect to 100 moles of the main component, and contents of said RE12O3, RE22O3 and RE32O3 satisfy RE12O3<RE22O3 and (RE12O3+RE22O3)?RE32O3.Type: GrantFiled: September 24, 2008Date of Patent: July 20, 2010Assignee: TDK CorporationInventors: Tetsuhiro Takahashi, Yasuo Watanabe, Toshihiko Kaneko, Masakazu Hosono, Tatsuya Ishii, Saori Takeda, Taisuke Masuko
-
Publication number: 20100168095Abstract: The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by A?.Type: ApplicationFiled: March 11, 2010Publication date: July 1, 2010Inventors: Teiji KIMURA, Noritaka KITAZAWA, Toshihiko KANEKO, Nobuaki SATO, Koki KAWANO, Koichi ITO, Eriko DOI, Mamoru TAKAISHI, Takeo SASAKI, Takehiko MIYAGAWA, Hiroaki HAGIWARA, Takashi DOKO
-
Patent number: 7737141Abstract: The present invention provides a most suitable prodrug of a cinnamide compound. The prodrug is represented by Formula (I) wherein Ra and Rb each denote a C1-6 alkyl group or the like; Xa denotes a methoxy group or a fluorine atom; Y denotes a phosphono group or the like; and A denotes a cyclic lactam derivative.Type: GrantFiled: July 25, 2007Date of Patent: June 15, 2010Assignee: Eisai R&D Management Co., Ltd.Inventors: Teiji Kimura, Koki Kawano, Noritaka Kitazawa, Nobuaki Sato, Toshihiko Kaneko, Koichi Ito, Mamoru Takaishi, Ikuo Kushida